Celldex Q3 net loss widens 13% year over year to $75.56 million
CLDX•Celldex Therapeutics’ third-quarter 2026 net loss widened 13% year over year to $75.56 million. Cash, cash equivalents and marketable securities totaled $650.3 million at September 30, enough to fund planned operations through 2028.
1. Quarterly results
Celldex Therapeutics’ third-quarter 2026 net loss widened 13% year over year to $75.56 million. Research and development expenses rose 7% to $67.41 million, while general and administrative expenses climbed 39% to $14.84 million.
2. Cash and trial results
Cash, cash equivalents and marketable securities totaled $650.3 million at September 30, sufficient to fund planned operations through 2028. Both Phase 3 barzolvolimab CSU studies met their primary and key secondary endpoints, and a BLA submission is anticipated in 2027.
